DeCure's autonomous Nephrology AI scientist is researching a drug-repurposing hypothesis for renal hypomagnesemia 3 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleRenal hypomagnesemia 3 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for renal hypomagnesemia 3 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Hypomagnesemia is defined as a serum magnesium concentration below 0.70 mmol/L. In a cohort of 232 critically ill ICU patients, the presence of hypomagnesemia was similar in those with or without acute kidney injury (47% versus 62%, P = 0.36). However, among patients who developed AKI, hypomagnesemia was present in 70% of those who did not recover renal function compared to 31% of those who did recover (P = 0.003). Multivariate analysis identified hypomagnesemia as an independent risk factor for non-recovery of renal function (P = 0.005). Mortality rates did not differ between patients with and without hypomagnesemia (P = 0.63).
In renal transplant recipients, the overall frequency of hypomagnesemia was 27.5% (65 of 236 patients). The frequency was 40% in the first 12 months after transplant, 26.1% between 12 and 60 months, and 26% after 60 months. Patients with tacrolimus levels above the target range had a higher frequency of hypomagnesemia: 40.9% versus 20.8% in the 12–60 month period (P = 0.018), and 44% versus 26% after 60 months (P = 0.046). Mean magnesium levels were lower in patients on tacrolimus than in those on cyclosporine (1.80 ± 0.18 versus 1.91 ± 0.25, P = 0.003). The effect of hypomagnesemia on graft function was statistically insignificant in all groups. No difference in hypomagnesemia frequency was found according to proton pump inhibitor use, gender, fasting blood glucose, or glomerular filtration rate.
Drug-induced hypomagnesemia is recognised as a multifactorial condition arising from impaired intestinal absorption, renal magnesium wasting, and the effects of medications including diuretics, antibiotics, antineoplastic agents, and immunosuppressants. Management strategies described in the literature include magnesium supplementation and adjunctive therapies such as amiloride and SGLT2 inhibitors to reduce renal magnesium losses. The significance of hypomagnesemia and the necessity for its treatment are described as under-recognised and underappreciated in clinical practice.
What remains missing is prospective trial data testing whether correcting hypomagnesemia in renal transplant recipients or critically ill patients with AKI improves renal recovery or graft outcomes. The available studies are observational or cross-sectional, and no randomised controlled trial has established a causal link between magnesium normalisation and improved renal function. Patient stratification by specific drug exposure, genetic susceptibility, or duration of hypomagnesemia has not been systematically addressed. Funding for such trials, rather than further descriptive work, is the clear gap.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
International Journal of Nephrology and Renovascular Disease · 2014 · 178 citations · open access
Hypomagnesemia: a clinical perspective
AbstractAlthough magnesium is involved in a wide spectrum of vital functions in normal human physiology, the significance of hypomagnesemia and necessity for its treatment are under-recognized and underappreciated in clinical practice. In the current review, we first present an overview of the clinical significance of hypomagnesemia and normal magnesium metabolism, with a focus on renal magnesium handling. Subsequently, we review the literature for both congenital and acquired hypomagnesemic conditions that affect the various steps in normal magnesium metabolism. Finally, we present an approach to the routine evaluation and suggested management of hypomagnesemia.
Hypomagnesemia as a risk factor for the non-recovery of the renal function in critically ill patients with acute kidney injury
AbstractBACKGROUND: The aim of this study was to evaluate the role of hypomagnesemia as a risk factor for the development of acute kidney injury (AKI) and non-recovery of renal function in critically ill patients. METHODS: A cohort study was conducted by collecting data from March to June 2011 in 232 patients who were admitted into an intensive care unit (ICU). Magnesium serum levels were measured daily during ICU stay. Hypomagnesemia was defined as an episode of serum magnesium concentration of <0.70 mmol/L during ICU stay. The Risk, Injury, Failure, Loss and End-stage kidney disease (RIFLE) criteria were used to define AKI. Renal function recovery was defined as an absence of AKI by the RIFLE criteria over a 48-h period, or at ICU discharge, in the patients who developed AKI during ICU stay. RESULTS: The presence of hypomagnesemia was similar in patients with or without AKI (47 and 62%, respectively, P = 0.36). The presence of hypomagnesemia was higher in patients who did not recover renal function when compared with patients who recovered renal function (70 versus 31%, P = 0.003). A multivariate analysis identified hypomagnesemia as an independent risk factor for non-recovery of renal function (P = 0.005). Patients with and without hypomagnesemia had similar mortality rates (P = 0.63). CONCLUSIONS: Hypomagnesemia was an independent risk factor for non-recovery of renal function in a cohort of critically ill AKI patients.
Journal of Toxicology Clinical Toxicology · 1996 · 23 citations
Hypermagnesemia Following an Acute Ingestion of Epsom Salt in a Patient with Normal Renal Function
AbstractCASE REPORT: Hypermagnesemia is a rare condition that commonly follows excessive therapeutic administration of magnesium sulfate to treat eclampsia of pregnancy. Signs and symptoms of this condition include extreme muscle weakness, loss of deep tendon reflexes, mental status depression, and cardiac dysrhythmias. Clinically significant hypermagnesemia following oral or rectal administration of magnesium containing products in patients with normal renal function is rare. We report a case of hypermagnesemia following massive Epsom salt ingestion that resulted in extreme musculoskeletal weakness and altered mentation.
The Clinical Spectrum of Acquired Hypomagnesemia: From Etiology to Therapeutic Approaches
AbstractHypomagnesemia is a frequent and often underrecognized electrolyte disturbance with important clinical consequences, especially in hospitalized and critically ill patients. This multifactorial condition arises from impaired intestinal absorption, renal magnesium wasting, and the effects of various medications. Magnesium, the second most abundant intracellular cation, is crucial in enzymatic and physiological processes; its deficiency is associated with neuromuscular, cardiovascular, and metabolic complications. This narrative review focuses on the mechanisms and clinical consequences of drug-induced hypomagnesemia, highlighting the major drug classes involved such as diuretics, antibiotics, antineoplastic agents, and immunosuppressants. Management strategies include magnesium supplementation and adjunctive therapies like amiloride and SGLT2 inhibitors to reduce renal magnesium losses. Recognizing and addressing drug-induced hypomagnesemia is essential to improve patient outcomes and prevent long-term complications.
Cukurova Anestezi ve Cerrahi Bilimler Dergisi · 2023 · 0 citations · open access
Hypomagnesemia and Calcineurin Inhibitors in Kidney Transplant Recipients
AbstractAim: Post-transplant hypomagnesemia is a frequently encountered and significant electrolyte disorder and is more common in patients using calcineurin inhibitors (CNIs). This study aimed to evaluate the frequency of hypomagnesemia and accompanying conditions in the outpatient follow-up of renal transplant recipients. Methods: This cross-sectional study included 236 renal transplant patients. Demographic characteristics of the patients and their biochemical values, including drug levels, were recorded. Results: Of the patients, 69 (29.2%) were female, and 194 (82.3%) were living donor recipients. The mean age of the entire group was 43.1 years. The frequency of hypomagnesemia was 40% (10/25) in the first 12 months, 26.1% (23/88) between the 12th and 60th months, 26% (32/123) after 60 months, and 27.5% (65/236) in all patients. In patients with higher levels of tacrolimus compared to those with the target level, the frequency of hypomagnesemia increased in those with a posttransplant period of 12-60 months (40.9% vs. 20.8%, p: 0.018) and over 60 months (44% vs. 26%, p: 0.046). In addition, the magnesium (Mg+2) level was lower in patients using tacrolimus compared to those using cyclosporine (CsA) (1.80±0.18 vs 1.91±0.25, p: 0.003). The effect of hypomagnesemia on graft functions was statistically insignificant in all groups. Conclusion: Hypomagnesemia is a common electrolyte disorder in the early and late periods after transplantation. In our study, hypomagnesemia did not differ according to proton pump inhibitor (PPI) use, gender, fasting blood glucose, and glomerular filtration rate. However, the frequency increased in patients using tacrolimus and those with above-target serum tacrolimus levels.
Böbrek Nakli Alıcılarında Hipomagnezemi Ve Kalsinörin İnhibitörleri
AbstractAim: Post-transplant hypomagnesemia is a frequently encountered and significant electrolyte disorder and is more common in patients using calcineurin inhibitors (CNIs). This study aimed to evaluate the frequency of hypomagnesemia and accompanying conditions in the outpatient follow-up of renal transplant recipients.Methods: This cross-sectional study included 236 renal transplant patients. Demographic characteristics of the patients and their biochemical values, including drug levels, were recorded.Results: Of the patients, 69 (29.2%) were female, and 194 (82.3%) were living donor recipients. The mean age of the entire group was 43.1 years. The frequency of hypomagnesemia was 40% (10/25) in the first 12 months, 26.1% (23/88) between the 12th and 60th months, 26% (32/123) after 60 months, and 27.5% (65/236) in all patients. In patients with higher levels of tacrolimus compared to those with the target level, the frequency of hypomagnesemia increased in those with a posttransplant period of 12-60 months (40.9% vs. 20.8%, p: 0.018) and over 60 months (44% vs. 26%, p: 0.046). In addition, the magnesium (Mg+2) level was lower in patients using tacrolimus compared to those using cyclosporine (CsA) (1.80±0.18 vs 1.91±0.25, p: 0.003). The effect of hypomagnesemia on graft functions was statistically insignificant in all groups.Conclusion: Hypomagnesemia is a common electrolyte disorder in the early and late periods after transplantation. In our study, hypomagnesemia did not differ according to proton pump inhibitor (PPI) use, gender, fasting blood glucose, and glomerular filtration rate. However, the frequency increased in patients using tacrolimus and those with above-target serum tacrolimus levels.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
